University of South Florida-Led preclinical study helps uncovered promising therapeutic target for Alzheimer’s disease.
Researchers have known that Apolipoprotein E (apoeE) is a major genetic risk factor for the development of Alzheimer’s disease, yet the protein tends to be understudied as a potential druggable target for the mind-robbing neurodegenerative disease.
A research team led by the University of South Florida Health (USF Health) Morsani College of Medicine reports that a novel apoE antagonist blocks apoE interaction with N-terminal amyloid precursor protein (APP). Moreover, this peptide antagonist, known as 6KApoEp, was shown to reduce Alzheimer’s-associated beta amyloid (β-amyloid) accumulation and tau pathologies in the brain, as well as improving learning and memory in mice genetically engineered to mimic symptoms of Alzheimer’s disease. The study was published online May 2 in Biological Psychiatry.
Many failed anti-amyloid therapies for Alzheimer’s disease have been directed against various forms of the protein β-amyloid, which ultimately forms clumps of sticky plaques in the brain. The presence of these amyloid plaques is one of the major hallmarks of Alzheimer’s disease.
The USF Health research findings suggests that disrupting apoE physical interaction with N-terminal APP may be a new disease-modifying therapeutic strategy for this most common type of dementia. Darrell Sawmiller, PhD, an assistant professor in the USF Health Department of Psychiatry & Behavioral Neurosciences, “This receptor-mediated mechanism plays a role in the development of Alzheimer’s disease. Overstimulation of APP by apoE may be an earlier, upstream event that signals other neurodegenerative processes contributing to the amyloid cascade.” Julie Tan, PhD, MD professor in the USF Health Department of Psychiatry & Behavioral Neurosciences “Our work further discovered an apoE derivative that can modulate and functional neuropathology in Alzheimer’s disease mouse models.”
Darrell Sawmiller, PhD, an assistant professor in the USF Health Department of Psychiatry & Behavioral Neurosciences